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Abstract
Background: We aimed to evaluate the influence of mammographic breast density at diagnosis on the risk of
cancer recurrence and survival outcomes in patients with invasive breast cancer after modified radical mastectomy.
Methods: This case-control study included 121 case-control pairs of women diagnosed with invasive breast cancer
between 2004 and 2009, and who had undergone modified radical mastectomy and had mammographic breast
density measured before or at diagnosis. Women with known locoregional recurrence or distant metastasis were
matched by pathological disease stage, age, and year of diagnosis to women without recurrence. Locoregional
recurrence was defined as recurrence in the ipsilateral chest wall, or axillary, internal mammary, or supraclavicular
nodes. The median follow-up duration was 84.0 months for case patients and 92.9 months for control patients.
Results: Patients with heterogeneously dense (50–75% density) and extremely dense (>75% density) breasts had an
increased risk of locoregional recurrence (hazard ratios 3.1 and 5.7, 95% confidence intervals 1.1–9.8 and 1.2–
34.9, p = 0.043 and 0.048, respectively) than did women with less dense breasts. Positive margins after surgery
also increased the risk of locoregional recurrence (hazard ratio 3.3, 95% confidence interval 1.3–8.3, p = 0.010).
Multivariate analysis that included dense breasts (>50% density), positive margin, no adjuvant radiotherapy,
and no adjuvant chemotherapy revealed that dense breasts were significant factors for predicting locoregional
recurrence risk (hazard ratio 3.6, 95% confidence interval 1.2–11.1, p = 0.025).
Conclusions: Our results demonstrate that dense breast tissue (>50% density) increased the risk of
locoregional recurrence after modified radical mastectomy in patients with invasive breast cancer. Additional
prospective studies are necessary to validate these findings.
Trial registration: The study is retrospectively registered with ClinicalTrials.gov, number NCT02771665, on May
11, 2016.
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Background
Breast cancer remains the most commonly diagnosed
cancer and the leading cause of cancer-related death in
women worldwide [1]. Mammographic breast density
(MBD) refers to the tissue composition of the breast.
The epithelium and fibrous tissue are radiodense and
appear white on a mammogram, whereas the fatty tissue
is radiolucent and appears black. MBD is calculated by
dividing the dense area by the total breast area. Larger
amounts of fibroglandular tissue in relation to fatty tis-
sue will lead to higher MBD values. High MBD has been
associated with increased risk of breast cancer [2, 3] and
local recurrence of invasive breast cancer after breast-
conserving surgery [4–6]. Several possible mechanisms
by which density could affect prognosis have been inves-
tigated. MBD has consistently been associated with
breast stromal composition, which is involved in tumor
progression [7–10].
Modified radical mastectomy (MRM) has been the pri-
mary treatment method for local breast cancer [11, 12].
According to published data, nearly one tenth of mastec-
tomized patients are at risk of locoregional recurrence
(LRR), and a quarter of patients are at risk of developing
distant metastases during follow up [13]. We hypothe-
sized that a high MBD and a microenvironment rich
in extracellular matrix (ECM) might promote cancers
that are more aggressive. This study therefore aimed
to evaluate the influence of high MBD on the risk of
recurrence in patients with invasive breast cancer
after MRM.
Methods
This study was approved by the Institutional Review
Board at National Taiwan University Hospital (approval
number 201401067RIND). The patients’ medical data
were anonymized prior to access and analysis. The
Institutional Review Board at NTUH waived the need
for written informed consent from the study subjects be-
cause all potentially patient-identifying information was
removed before data analysis.
Between January 2004 and December 2009, a total of
4089 women were diagnosed and treated with invasive,
non-metastatic breast cancer at our institution, 2011 of
whom underwent definitive MRM. Approximately 20%
of the MRM cases were diagnosed and staged at regional
hospitals and later referred to our institution (the official
tertiary referral hospital) for definitive surgery; conse-
quently, the pre-surgery mammograms were not regis-
tered in our image database. Moreover, the image
database in our institution underwent a major upgrade
in 2005, which resulted in a partial data loss. Therefore,
at the time of analysis, there were 1056 pre-surgery
mammograms in our image database for MBD measure-
ment. Among these 1056 patients who received MRM
and had pre-operative MBD measured, 38% had stage I
disease, 34% had stage II disease, and 28% had stage III
disease. Seventy were excluded from the analysis because
the patients had received neoadjuvant chemotherapy.
Recurrence was categorized as locoregional (ipsilateral
chest wall or axillary, internal mammary, or supraclavi-
cular nodes) or distant metastasis (DM). A total of 121
patients experienced either LRR or DM. The patient
flow chart is shown in Fig. 1.
Case control matching was based on pathological dis-
ease stage as defined by the American Joint Committee
on Cancer, patient age, and year of diagnosis. Each
patient with recurrence was matched with at least one
control. Control patients had breast cancer but no recur-
rence. Matching patients according to exact disease
stage, age, and year of diagnosis was possible in only a
few instances; therefore, the age criterion was relaxed to
allow age differences within 3 years. Subject demo-
graphic information, self-reported height and weight,
breast cancer risk factors, tumor characteristics (e.g.,
tumor size, axillary node status, and surgery margin),
and adjuvant treatment information were obtained from
the Cancer Registry Medical Information Management
Office at our institution. Ultimately, 121 women with
LRR or DM were matched to 121 women without recur-
rence. The patient flow chart is shown in Fig 1.
Fig. 1 Patient flowchart. Between January 2004 and December 2009,
a total of 1056 patients received modified radical mastectomy (MRM)
and had pre-operative mammographic breast density (MBD) measured
at our institution. Seventy women who received neoadjuvant
chemotherapy were excluded. Recurrences were categorized as
locoregional (ipsilateral chest wall or axillary, internal mammary,
or supraclavicular nodes) or distant metastasis. Each patient with
known locoregional recurrence or distant metastasis (n = 121, the
case group) were matched to at least one patient without recurrence
(the control group) by pathological disease stage, age, and year
of diagnosis
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Tumors scored as human epidermal growth factor re-
ceptor 2 (Her2) 3+ or as 2+ with HER2 amplification
(determined via fluorescence in situ hybridization, ratio
≥2) were considered Her2-positive. Owing to our
country’s national health insurance policy, our national
health insurance program completely covers hormone-
receptor-positive patients, and selectively covers adju-
vant trastuzumab therapy in patients with Her2-positive
disease and positive nodal status.
Follow-up analysis was conducted using a comprehen-
sive protocol and the relevant data available on 10
September 2016. All patients were followed up every
3 months in the first 2 years, every 4 months in the third
and fourth years, and then every 6 months until recur-
rence or death. The follow-up visits included physical
examinations, determination of tumor marker expres-
sion, and imaging studies if required. Recurrence was
defined only by the site of the first relapse (i.e., locore-
gional or distant). The median length of follow up in
case patients was 84.0 months (range 23.9–148.4 months)
and in control patients it was 92.9 months (range 18.2–
150.7 months). All but two patients were followed up for
at least 36 months [14]; the exceptions were one control
patient with a follow-up period of 23.9 months and one
case patient with a follow-up period of 18.2 months.
MBD measurements
MBD was defined on a mammogram of the contralateral
breast (i.e., the breast not affected by cancer) taken any
time during the year preceding the MRM. MBDs in all
patients were measured using a previously described,
validated, computer-based interactive threshold method
[15]. A dedicated mammographic unit (GE, Senographe
DMR, Buc, Cedex, France) with an 18 × 24-cm Min-R M
or Min-R 2000 screen/film system (Eastman Kodak,
Rochester, NY, USA) was used for all patients [16]. All
mammographic images were read by radiologists with at
least 5 years of experience in breast imaging. We used
the public ImageJ software to establish the semi-
automated process for evaluating MBD on digital mam-
mograms [17]. The mediolateral oblique was the pre-
ferred mammographic projection for MBD evaluation.
In brief, each digitized mammogram was displayed on
a computer screen, and a threshold was selected by the
operator to isolate the breast from the surrounding
background (Fig. 2). A second threshold was set to iden-
tify areas of density. The computer-assisted method di-
vided the mammographic image according to a gray-
value distribution, with darker regions indicating fatty
tissue and lighter regions representing dense tissue. The
MBD percentage was determined by measuring the total
breast area and the number of pixels outlined in the
dense regions using the computer software. The breast
composition of each patient, as revealed by the
mammograms, was estimated according to the American
College of Radiology (ACR) lexicon definition before
2013. Specifically, ACR 1 indicates <25% density and
that “the breast is almost entirely fat.” ACR 2 indicates
25–50% density and that “there are scattered fibrogland-
ular tissues.” ACR 3 indicates 50–75% density and that
“the breast is heterogeneously dense.” ACR 4 indicates
>75% density and that “the breast is extremely dense.”
There was strong correlation between the externally vali-
dated results using the ACR lexicon definition inter-
preted by the radiologists and the computer-assisted
method (R2 = 0.906, p <0.001).
Statistical analysis
Statistical assistance was provided by the Clinical Trial
Bioinformatics and Statistical Center, Training Center,
and Pharmacogenomics Laboratory, founded by the
Fig. 2 Mammographic breast density measurement using the
computer-assisted method. a Left mediolateral oblique projection
mammograms were used to assess women with right-sided breast
cancer. b A threshold was selected by the operator to isolate the
breast from the surrounding background. c A second threshold was
set to identify areas of density. d The mammographic breast density
(MBD) percentage was determined by measuring the total area of
the breast and the number of pixels outlined in the dense regions
using the computer software. e The estimated MBD was classified
according to the American College of Radiology (ACR) lexicon
definition before 2013. Specifically, ACR 1 indicates <25% density
and that “the breast is almost entirely fat.” ACR 2 indicates 25–50%
density and that “there are scattered fibroglandular tissues.” ACR 3
indicates 50–75% density and that “the breast is heterogeneously
dense.” ACR 4 indicates >75% density and that “the breast is
extremely dense”
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National Research Program for Biopharmaceuticals at
the Ministry of Science and Technology (MOST 103-
2325-B-002-033) in our country, and the Department of
Medical Research at our institution. The Statistical
Package for Social Sciences for Windows, version 17.0
(SPSS Inc., Chicago, IL, USA), was used for statistical
analysis. Survival data were confirmed with the Cancer
Registry Medical Information Management Office at our
institution. All events were calculated from the date of
MRM completion.
Descriptive characteristics were compared using the
chi-squared test for categorical variables and the paired
Student’s t test for continuous variables. We assessed the
association between MBD and recurrence or death from
any cause using a conditional logistic regression model.
Conditional logistic regression analyses with stratified
Cox models were used to evaluate the potential risk fac-
tors for patients with LRR. Prognostic variables found to
be significant at p <0.20 on univariate analysis were in-
cluded in a multivariate model and then removed, one
by one, by eliminating the variable with the greatest p
value and retesting the remaining variables using the
Cox proportional hazards regression model. Overall, a p
value ≤0.05 was considered statistically significant.
Results
The patient flow chart is shown in Fig 1. We recruited
121 case-control pairs for our analysis, which included
43 case patients who experienced LRR and 78 who expe-
rienced DM. In the 43 LRR case patients, there were 18
chest wall, 17 axillary node, one internal mammary
node, three supraclavicular node, one synchronous chest
wall and internal mammary node, one synchronous in-
ternal mammary and supraclavicular node, and two syn-
chronous chest wall and axillary node recurrences.
Table 1 lists the clinical characteristics of the case pa-
tients and control subjects, who were matched according
to pathological disease stage, age, and year of diagnosis.
The median age was 51.6 years (range 27–94 years), and
the mean body mass index (BMI) was 23.6 kg/m2 (range
15.4–38.1 kg/m2). Among the case and control patients,
38.0% of the patients had stage III disease. There were
no significant differences in tumor size or number of
positive axillary nodes between case patients and control
patients. Triple-negative breast cancers were observed in
21.5% of case patients and 17.4% of control patients
(p = 0.417). Dense breasts (MBD >50%) were observed
more frequently in the case patients than in the con-
trol patients, although this difference was not statisti-
cally significant (43.0% vs. 32.2%, p = 0.092).
At the time of analysis, 53 case patients and eight con-
trol patients had died. The median length of follow up
was 84.0 months (range 23.9–148.4 months) in case pa-
tients and 92.9 months (range 18.2–150.7 months) in
control patients. Statistically significant differences in
the likelihood of LRR, DM, or death from any cause
were observed between women with MBD values <50%
and those with MBD values between 50% and 75% or
MBD >75%. As shown in Table 2, patients with hetero-
geneously dense (50–75% density) and extremely dense
(>75% density) breasts had an increased risk of LRR
(hazard ratios 3.1 and 5.7, 95% confidence intervals 1.1–
9.8 and 1.2–34.9, p = 0.043 and 0.048, respectively). We
found no association between MBD and the risk of dis-
tant metastasis or death from any cause.
The results of the univariate analysis of potential fac-
tors affecting LRR in the 121 case-control pairs are
shown in Table 3. There was no significant correlation
between LRR and tumor size, number of positive axillary
nodes, type of adjuvant therapy, triple-negative cancer,
or BMI. However, positive margins after surgery in-
creased the risk of LRR (hazard ratio 3.3, 95% confidence
interval 1.3–8.3, p = 0.010). Although not significant, no
adjuvant radiotherapy (p = 0.120) or no adjuvant chemo-
therapy (p = 0.166) also increased the risk of LRR.
To determine which factors were independently asso-
ciated with LRR, we performed stepwise elimination lo-
gistic regression analysis using the Cox proportional
hazards regression model and the variables with p values
<0.20 in the univariate analysis (no adjuvant radiother-
apy, no adjuvant chemotherapy, positive margins, and
MBD >50%). On multivariate analysis (Table 4), dense
breasts were a significant factor for predicting risk of
LRR (hazard ratio 3.6, 95% confidence interval 1.2–11.1,
p = 0.025).
Discussion
The present study shows that high MBD is a significant
independent predictor of LRR after MRM in patients
with invasive breast cancer. To our knowledge, it is one
of the few studies published to date to have evaluated
breast density as a predictor of breast cancer recurrence,
with generally consistent results [4–6, 18]. Park et al. [5]
conducted a case-control study of 136 patients with in-
vasive breast cancer who underwent breast-conserving
surgery and radiotherapy, and found that those with the
highest breast density (>75%) had a greater than fourfold
incidence of local, but not distant, disease recurrence
compared to those with low breast density (<25%). Cil et
al. [6] conducted a retrospective cohort study of 355 pa-
tients who underwent breast-conserving surgery for in-
vasive breast cancer and demonstrated fivefold higher
risk of local disease recurrence in patients with high
(>50%) versus low <25%) mammographic density.
Eriksson et al. [4] conducted a case-only study of 1774
patients who underwent breast-conserving surgery or
mastectomy for invasive breast cancer and found nearly
twofold higher risk of locoregional recurrence in women
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Table 1 Characteristics between patients who did or did not experience recurrences
Control group Case group
n = 121 Percentage n = 121 Percentage P value
Age (years)
mean (range) 51.4 (28–89) 51.6 (27–94) 0.738*
<40 15 12.4 19 15.7 0.725†
40–59 87 71.9 82 67.8
>60 19 15.7 20 16.5
AJCC stage (pathological)
I 24 19.8 24 19.8 1.000†
IIA 33 27.3 33 27.3
IIB 18 14.9 18 14.9
IIIA 20 16.5 20 16.5
IIIB 2 1.7 2 1.7
IIIC 24 19.8 24 19.8
Tumor size (mm)
0–10 19 15.7 19 15.7 0.911†
10 − 19 19 15.7 22 18.2
20 − 50 68 56.2 63 52.1
>50 15 12.4 17 14.0
Positive axillary nodes
None 47 38.8 49 40.5 0.956†
1–3 32 26.4 32 26.4
>4 42 34.7 40 33.1
Margin
Negative 112 92.6 106 87.6 0.197
Positive 9 7.4 15 12.4
Estrogen/progesterone receptor status
Negative 46 38.0 44 36.4 0.790†
Positive 75 62.0 77 63.6
Her2 statusa
Negative 92 76.0 88 72.7 0.556
Positive 29 24.0 33 27.3
Triple-negative cancer
Negative 100 82.6 95 78.5 0.417
Positive 21 17.4 26 21.5
MBD quartiles
1 (0–25%) 29 24.0 10 8.3 0.023†
2 (25–50%) 53 43.8 59 48.8
3 (50–75%) 32 26.4 41 33.9
4 (75–100%) 7 5.8 11 9.1
Adjuvant chemotherapy
No 26 21.5 21 17.4 0.417†
Yes 95 78.5 100 82.6
Huang et al. Breast Cancer Research  (2016) 18:120 Page 5 of 9
with MBD >25% versus <25%, and MBD was not associ-
ated with either distant recurrence or survival.
To reduce the possibility of recurrence being over-
looked, our institution has a comprehensive follow-up
protocol. When all women with invasive breast cancer
treated by MRM at our institution were analyzed, the
LRR rate was 4.1% (43 of 1056 patients), and among
these patients, 38% had stage I disease, 34% had stage II
disease, and 28% had stage III disease. Among the 121
case patients, nearly 60% had stage I/II disease and
nearly 40% had stage III disease. The lack of correspond-
ence between the distribution of disease stage in the
overall cohort (1056 patients who received MRM and
had pre-operative MBD measured) and case cohort (121
patients with 43 LRRs and 78 DMs) is reasonable, as the
case patients were not randomly selected from the over-
all cohort. Half of the case patients with an LRR had re-
ceived post-mastectomy radiotherapy, and our LRR rate
of 4.1% is consistent with the LRR rates (1.6–8.1%) ob-
tained in a study by the Early Breast Cancer Trialists’
Collaborative Group [19], in which patients received
mastectomy and adjuvant radiotherapy.
The percentage of patients with positive nodes was
not different between the control cohort and case cohort
(p = 0.956, Table 1). We did not observe a significant dif-
ference in the hazard ratio among patients with positive
nodes, which may be due to the case-control study de-
sign, as we matched the case patients to the control pa-
tients with the same disease stage to eliminate this
confounding factor, as there was strong correlation be-
tween the tumor, node, metastatis (TNM) staging system
and locoregional recurrence.
We found no significant impact of breast density on
distant recurrence or death. Risk factors for LRR are not
the same as those for death because there are reasonable
salvage treatments, which may partly explain why high
breast density is not significantly correlated with death.
Gierach et al. [20] reported that breast imaging-
reporting and data system (BIRADS) density categories
are not related to the risk of death, which is consistent
Table 1 Characteristics between patients who did or did not experience recurrences (Continued)
Adjuvant hormone therapy
No 47 38.8 50 41.3 0.694†
Yes 74 61.2 71 58.7
Adjuvant target therapy
No 100 82.6 102 84.3 0.729†
Yes 21 17.4 19 15.7
Adjuvant radiotherapy
No 59 48.8 64 52.9 0.520†
Yes 62 51.2 57 47.1
BMI (kg/m2)
mean (range) 24.0 (16.2–35.4) 23.1 (15.4–38.1) 0.272*
Normal (<25) 85 70.2 80 64.5 0.627†
Overweight (25–30) 28 23.1 33 27.3
Obese (>30) 8 6.6 10 8.3
a Human epidermal growth factor receptor 2 (Her2) status indicated all Her2 (3+)-positive tumors and Her2 (2+)- positive tumors with Her2 amplification investigated by
fluorescence in situ hybridization; ratio ≥ 2. AJCC American Joint Committee on Cancer, MBD mammographic breast density, BMI body mass index. *Significance tested
using paired Student’s t test. †Significance tested using Pearson’s chi-square test
Table 2 Hazard ratios of cancer recurrence and survival outcome based on MBD quartiles (n = 121 case-control pairs)
Locoregional recurrence Distance metastasis Death
HR 95% CI P value* HR 95% CI P value* HR 95% CI P value*
MBD quartiles
1, 2 (0–50%) 1.0 1.0 1.0
3 (50–75%) 3.1 1.1–9.8 0.043† 5.7 0.0–21.9 0.492 3.2 0.9–10.1 0.062
4 (75–100%) 5.7 1.2–34.9 0.048† 10.4 0.8–37.2 0.311 2.2 0.3–13.7 0.409
MBD mammographic breast density, HR hazard ratio, CI confidence interval. *Significance tested using conditional logistic regression analyses by stratified Cox
model. †P value <0.05 was considered statistically significant
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with our study finding. Interestingly, they pointed out
that patients with breast cancer with a low breast dens-
ity, and who are obese (BMI >30 kg/m2) have increased
risk of death; this is probably due to increased BMI, lar-
ger adipocyte size, and breast microenvironments that
provide a stimulus for tumor growth, which was not
seen in our study. More comprehensive information, in-
cluding recurrence patterns, health comorbidities, and
cause of death, is needed to identify the impact of obes-
ity in patients with low breast density. There were only a
few obese patients (one tenth) in our cohort, whereas
one fourth of patients were obese in the Gierach study;
Table 3 Univariate analysis of risk factors associated with locoregional recurrence (n = 121 case-control pairs)
Control group Case group (all patients) Case group (only patients with LRR)
n = 121 n = 121 n = 43 HR 95% CI P value*
MBD quartiles
1, 2 (0– 50%) 82 69 26 1.0
3 (50– 75%) 32 41 13 3.1 1.1–9.8 0.043†
4 (75– 100%) 7 11 4 5.7 1.2–34.9 0.048†
Tumor size (mm)
0–10 19 19 8 1.0
10 − 19 19 22 12 2.5 0.6–10.1 0.187
20 − 50 68 63 15 1.8 0.2–3.8 0.806
>50 15 17 8 4.1 0.3–57.5 0.291
Positive axillary nodes
None 47 49 15 1.0
1–3 32 32 12 0.6 0.1–2.5 0.477
>4 42 40 16 0.8 0.1–6.4 0.731
Margin
Negative 112 106 37 1.0
Positive 9 15 6 3.3 1.3–8.3 0.010†
Adjuvant chemotherapy
Yes 95 100 32 1.0
No 26 21 11 2.0 0.7–5.3 0.166
Adjuvant hormone therapy
Yes 74 71 22 1.0
No 47 50 21 2.0 0.2–22.1 0.571
Adjuvant target therapy
Yes 21 19 6 1.0
No 100 102 37 6.5 0.0–56.5 0.471
Adjuvant radiotherapy
Yes 62 57 20 1.0
No 59 64 23 1.6 0.6–3.9 0.120
Triple-negative cancer
Negative 100 95 34 1.0
Positive 21 26 9 2.0 0.5–8.0 0.327
BMI (kg/m2)
Normal (<25) 85 80 26 1.0
Overweight (25–30) 28 33 13 1.2 0.6–2.4 0.708
Obese (>30) 8 10 4 1.1 0.3–3.8 0.931
LRR locoregional recurrence, MBD mammographic breast density, BMI body mass index, HR hazard ratio, CI confidence interval. *Significance tested using
conditional logistic regression analyses by stratified Cox model. †P value <0.05 was considered statistically significant
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hence, obesity is less likely to be positively correlated
with death in our cohort due to the small number of pa-
tients. Results from Western society may not be applic-
able to our populations because of the unique etiology,
molecular subtype, invasion pattern, recurrence, or prog-
nosis among our patients with breast cancer [21].
Our results indicate that high MBD values independ-
ently confer greater LRR risk upon women with breast
cancer, but not distant metastasis. MBD reflects the
breast composition, and higher values indicate larger
proportions of fibroglandular elements and extracellular
matrix (ECM) relative to adipose stroma [8, 9]. An ab-
normal microenvironment and dysregulated cell–ECM
matrix signaling have been associated with breast cancer
invasion, metastasis, and therapeutic resistance [13, 22].
From a biological perspective, high MBD is suggestive of
enhanced migratory, invasive, and metastatic behavior
resulting from interactions of the ECM with the sur-
rounding tumor and blood vessel walls [7, 10]. Increased
ECM signaling, and particularly β1-integrin expression,
has also been associated with reduced survival in pa-
tients with invasive breast cancer [23]. One hypothesis
for LRR after mastectomy in patients with high MBD is
that MBD can increase the risk of self-seeding, a process
in which disseminated tumor cells return and colonize
the primary tumor site [24]. In contrast to metastasis,
which requires the ability to enter, survive, and colonize
a new site, self-seeding needs little or no adaptation, as
the circulating tumor cell returns to a familiar environ-
ment [25]. This would explain the phenomenon of post-
mastectomy LRR.
There has been considerable interest in modifiable risk
factors that may prevent recurrent disease and in the po-
tential use of breast density as an intermediate risk bio-
marker. We performed multivariate regression analysis
to account for possible collinearities, including adjuvant
radiotherapy or chemotherapy [26], positive margin, and
MBD >50%, to determine if MBD independently confers
increased risk of LRR. Our data support the hypothesis
that MBD may be used as a practical prognostic factor.
However, it remains unclear whether MBD can be used
to discriminate greater LRR risk in all breast cancer pa-
tients. This is an issue to be addressed in future larger
studies.
Our study was limited by its case-control design. In
addition, half of the patients in the initial cohort had to
be excluded from the analysis because their pre-surgery
mammograms were not available. This exclusion is a po-
tential source of bias if it was not random. However,
analysis of the comparison statistics confirmed that the
excluded patients did not differ from those included in
the analysis in important factors such as disease stage,
age, and year of diagnosis.
Conclusions
In the present study, we found that high MBD (>50%
density) is a significant independent predictor of LRR
after MRM for invasive breast cancer. The results of this
study might influence patient management and may be
helpful to physicians when making clinical decisions.
Additional prospective studies are necessary to validate
these findings.
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patients' medical data were anonymized prior to access and analysis. The
Institutional Review Board at NTUH has waived the need for written
informed consent from study subjects because all potentially patient-
identifying information was removed prior to data analysis.
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